A310210 Stock Overview
Researches, develops, and discovers small molecule kinase inhibitors in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Voronoi, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩86,100.00 |
| 52 Week High | ₩125,900.00 |
| 52 Week Low | ₩28,350.00 |
| Beta | 1.99 |
| 1 Month Change | 7.63% |
| 3 Month Change | -20.28% |
| 1 Year Change | 155.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 252.03% |
Recent News & Updates
Voronoi (KOSDAQ:310210) Is In A Good Position To Deliver On Growth Plans
Jan 03
Health Check: How Prudently Does Voronoi (KOSDAQ:310210) Use Debt?
Sep 20Shareholder Returns
| A310210 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 7.2% | 0.4% | -0.7% |
| 1Y | 155.5% | 25.2% | -5.5% |
Return vs Industry: A310210 exceeded the KR Biotechs industry which returned 28.1% over the past year.
Return vs Market: A310210 exceeded the KR Market which returned -2.2% over the past year.
Price Volatility
| A310210 volatility | |
|---|---|
| A310210 Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A310210's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A310210's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 130 | n/a | voronoi.io |
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer.
Voronoi, Inc. Fundamentals Summary
| A310210 fundamental statistics | |
|---|---|
| Market cap | ₩1.55t |
| Earnings (TTM) | -₩38.88b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-39.8x
P/E RatioIs A310210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A310210 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩38.88b |
| Earnings | -₩38.88b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17k |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did A310210 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 09:24 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Voronoi, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyun-soo Ha | Yuanta Securities Korea Co., Ltd. |